Nebenwirkungen · Ozempic
Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-135985 · Präparat HOS-097800
Hypoglycaemia No episodes of severe hypoglycaemia were observed when semaglutide was used as monotherapy. Severe hypoglycaemia was primarily observed when semaglutide was used with a sulfonylurea (1.2% of subjects, 0.03 events/patient year) or insulin (1.5% of subjects, 0.02 events/patient year). Few episodes (0.1% of subjects, 0.001 events/patient year) were observed with semaglutide in combination with oral antidiabetics other than sulfonylureas.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage b2394c95fedcba27aeb9bd2b91586b466ec18b1fc84c07d939d4b1960af1b563 · Zeichen 5978–6430 im Abschnitt